A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector & Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA)

Trial Profile

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector & Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA)

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 17 Dec 2017

At a glance

  • Drugs Vocimagene amiretrorepvec-flucytosine gene therapy (Primary) ; Bevacizumab; Lomustine; Temozolomide; Temozolomide
  • Indications Anaplastic astrocytoma; Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Toca 5
  • Sponsors Tocagen
  • Most Recent Events

    • 14 Nov 2017 Status changed from active, no longer recruiting to recruiting.
    • 26 Oct 2017 Planned End Date changed from 1 Sep 2019 to 1 Mar 2023.
    • 26 Oct 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top